Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Calquence

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

    In 2022, nearly one million new patients were diagnosed with gastric cancer

    - PMLiVE

    AstraZeneca announces $2bn investment in US manufacturing

    The new and expanded facilities will support production of rare disease drug treatments

    - PMLiVE

    AstraZeneca reports positive results from rare disease trial

    HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

    - PMLiVE

    AstraZeneca reports positive results from phase 3 blood pressure trial

    The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

    - PMLiVE

    AstraZeneca to invest $4.5bn in US manufacturing facility

    The investment will further support the company’s growing oncology pipeline

    - PMLiVE

    AstraZeneca announces agreement with US government to reduce medicine costs

    The pharma company is the latest to offer direct-to-consumer purchasing

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

    Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

    Innovative Trials

    - PMLiVE

    AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

    Approximately 6,600 people are diagnosed with liver cancer every year in the UK

    - PMLiVE

    Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

    Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links